Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics

Drug Discovery Today

Volumn 19, Issue 12, 2014, Pages 1945-1952

  Verhoef, Johan J F ^a   Carpenter, John F ^b   Anchordoquy, Thomas J ^b   Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASPARAGINASE MACROGOL; COMPLEMENT; DOXORUBICIN; EPITOPE; INTERFERON; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NANOCARRIER; PEGINESATIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; RECOMBINANT ERYTHROPOIETIN; ALPHA INTERFERON; ASPARAGINASE; MACROGOL DERIVATIVE; PEPTIDE; URATE OXIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANALYTIC METHOD; ANEMIA; B LYMPHOCYTE; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GOUT; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; OVARY CANCER; PHAGOCYTE; PHAGOCYTOSIS; POLYMERIZATION; REVIEW; SPLEEN; ANALOGS AND DERIVATIVES; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES; ASPARAGINASE; COMPLEMENT ACTIVATION; DOXORUBICIN; HUMANS; INTERFERON-ALPHA; PEPTIDES; POLYETHYLENE GLYCOLS; URATE OXIDASE;

EID: 84918789743     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.015     Document Type: Review

References (78)

1. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
2. N. Jenkins Modifications of therapeutic proteins: challenges and prospects Cytotechnology 53 2007 121 125
3. P.J. Carter Introduction to current and future protein therapeutics: a protein engineering perspective Exp. Cell Res. 317 2011 1261 1269
4. A. Abuchowski Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 252 1977 3578 3581
5. A. Abuchowski Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252 1977 3582 3586
6. J.J.F. Verhoef, and T.J. Anchordoquy Questioning the use of PEGylation for drug delivery Drug Deliv. Transl. Res. 3 2013 499 503
7. T.M. Allen, and A. Chonn Large unilamellar liposomes with low uptake into the reticuloendothelial system FEBS Lett. 223 1987 42 46
8. R.P. Garay Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents Expert Opin. Drug Deliv. 9 2012 1319 1323
9. D.S. Pisal Delivery of therapeutic proteins J. Pharm. Sci. 99 2010 2557 2575
10. T. Ishida, and H. Kiwada Anti-polyethyleneglycol antibody response to PEGylated substances Biol. Pharm. Bull. 36 2013 889 891
11. T. Shimizu Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon Immunobiology 218 2013 725 732
12. H. Schellekens Immunogenicity of therapeutic proteins: clinical implications and future prospects Clin. Ther. 24 2002 1720 1740
13. H. Koide T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes Int. J. Pharm. 392 2010 218 223
14. I. Hamad Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process Mol. Immunol. 46 2008 225 232
15. E.T. Dams Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes J. Pharmacol. Exp. Ther. 292 2000 1071 1079
16. T. Shimizu Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response Biol. Pharm. Bull. 35 2012 1336 1342
17. J. Szebeni Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
18. T. Ishida The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats J. Control. Release 126 2008 162 165
19. European Medicines Agency EPAR Summary for the Public: PegIntron 2012
20. J.K. Armstrong Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 110 2007 103 111
21. K-U. Eckardt Anaemia: the safety and efficacy of peginesatide in patients with CKD Nat. Rev. Nephrol. 9 2013 192 193
22. A. Mikhail Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis J. Blood Med. 3 2012 25 31
23. J.S. Sundy Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials J. Am. Med. Assoc. 306 2011 711 720
24. C. Scagnolari Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α Clin. Microbiol. Infect. 18 2012 1033 1039
25. H. Schellekens The immunogenicity of polyethylene glycol: facts and fiction Pharm. Res. 30 2013 1729 1734
26. Y. Liu A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers J. Pharmacol. Toxicol. Methods 64 2011 238 245
27. A.W. Richter, and E. Akerblom Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins Int. Arch. Allergy Appl. Immunol. 70 1983 124 131
28. A.W. Richter, and E. Akerblom Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors Int. Arch. Allergy Appl. Immunol. 74 1984 36 39
29. J. Szebeni Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome Nanomed. Nanotechnol. Biol. Med. 8 2012 176 184
30. A. Chanan-Khan Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437
31. X. Wang Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes J. Control. Release 119 2007 236 244
32. T. Ishida Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes J. Control. Release 112 2006 15 25
33. A. Nagao Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application Int. J. Pharm. 441 2013 395 401
34. I.C. Macdougall Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis N. Engl. J. Med. 368 2013 320 332
35. S. Fishbane Peginesatide in patients with anemia undergoing hemodialysis N. Engl. J. Med. 368 2013 307 319
36. P.G.H. Gell, and R.R.A. Coombs Clinical Aspects of Immunology 1963 Blackwell Scientific
37. M. Steiner Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia Pediatr. Blood Cancer 49 2007 640 642
38. R. Pieters l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase Cancer 117 2011 238 249
39. G. Garratty Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs Transfus. Med. Rev. 18 2004 245 256
40. H. Tillmann High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon J. Hepatol. 52 2010 S129
41. A.T. Eggebeen Gout: an update Am. Fam. Physician 76 2007 801 808
42. J.S. Bomalaski Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies J. Rheumatol. 29 2002 1942 1949
43. Food and Drug Administration KRYSTEXXA™ (pegloticase) for intravenous infusion 2009 BLA No. 125293
44. N.J. Ganson Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a Phase I trial of subcutaneous PEGylated urate oxidase Arthritis Res. Ther. 8 2006 R12
45. P.E. Lipsky Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout Arthritis Res. Ther. 16 2014 R60
46. C-J. Chen MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals J. Clin. Invest. 116 2006 2262 2271
47. S.G. Maher Interferon: cellular executioner or white knight? Curr. Med. Chem. 14 2007 1279 1289
48. M.G. Tovey, and C. Lallemand Safety, tolerability, and immunogenicity of interferons Pharmaceuticals 3 2010 1162 1186
49. M.P. Manns Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
50. P. Bailon Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C Bioconjug. Chem. 12 2001 195 202
51. T. Santantonio Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon J. Hepatol. 45 2006 759 761
52. X. Hu A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology J. Clin. Pharmacol. 52 2012 798 808
53. G. Antonelli Biological basis for a proper clinical application of alpha interferons New Microbiol. 31 2008 305 318
54. A.S. Abu Lila The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage J. Control. Release 172 2013 38 47
55. T. Ishida PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner J. Control. Release 122 2007 349 355
56. T. Ishihara Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles Pharm. Res. 26 2009 2270 2279
57. C. Li Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan Int. J. Pharm. 443 2013 17 25
58. A. Cerutti Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes Nat. Rev. Immunol. 13 2013 118 132
59. C.G. Vinuesa, and P-P. Chang Innate B cell helpers reveal novel types of antibody responses Nat. Immunol. 14 2013 119 126
60. A.P.N.A. Porto Assessment of splenic function Eur. J. Clin. Microbiol. Infect. Dis. 29 2010 1465 1473
61. M. Ichihara Anti-PEG IgM response against PEGylated liposomes in mice and rats Pharmaceutics 3 2010 1 11
62. T.L. Cheng Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM Bioconjug. Chem. 10 1999 520 528
63. M.R. Sherman Role of the methoxy group in immune responses to mPEG-protein conjugates Bioconjug. Chem. 23 2012 485 499
64. J.K. Armstrong The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol) F.M. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser 147 168
65. R.P. Garay, and J-P. Labaune Immunogenicity of polyethylene glycol (PEG) Open Conf. Proc. J. 2 2011 104 107
66. M.G.P. Saifer Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins Mol. Immunol. 57 2014 236 246
67. Y.R. Carrasco, and F.D. Batista B cell recognition of membrane-bound antigen: an exquisite way of sensing ligands Curr. Opin. Immunol. 18 2006 286 291
68. S.B. Gauld Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling Nat. Immunol. 6 2005 1160 1167
69. C.A. Janeway The Immune System in Health and Disease 5th edn 2001 Garland Science
70. K.Y. Helmy CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens Cell 124 2006 915 927
71. J. Szebeni Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model J. Control. Release 160 2012 382 387
72. A.J. Bradley Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs Transfusion (Paris) 41 2001 1225 1233
73. R. Chapanian Influence of polymer architecture on antigens camouflage, CD47 protection and complement mediated lysis of surface grafted red blood cells Biomaterials 33 2012 7871 7883
74. J. Szebeni Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity Toxicology 216 2005 106 121
75. S.M. Moghimi Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead J. Control. Release 146 2010 175 181
76. S. Qiu Complement activation associated with polysorbate 80 in beagle dogs Int. Immunopharmacol. 15 2013 144 149
77. T. Ishida Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection J. Control. Release 115 2006 251 258
78. F.M. Veronese PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Springer